<DOC>
	<DOCNO>NCT02569996</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability long-term maintenance therapy rituximab participant advance follicular lymphoma positive response first-line treatment rituximab-containing regimen . The anticipated time study treatment 2 year , target sample size 124 individual .</brief_summary>
	<brief_title>A Study Long-Term Rituximab ( MabThera ) Maintenance Therapy Participants With Advanced Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult participant great ( &gt; ) 18 year age Histologically confirm follicular lymphoma Grade 1 , 2 , 3a lymph node biopsy within 4 month induction treatment No previous antilymphoma treatment induction chemotherapy ( firstlinetreated participant eligible ) Verified complete partial remission firstline induction therapy include rituximab Grade 3b follicular lymphoma Transformation highgrade lymphoma ( except Grade 3a ) previously exist follicular lymphoma Presence central nervous system lymphoma Acquired immunodeficiency syndromerelated lymphoma Other primary malignancy ( squamous cell cancer skin situ cancer cervix ) participant diseasefree great equal ( &gt; = ) 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>